TISIDB

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type IV membrane protein.
Domain	PF05739 SNARE domain PF00804 Syntaxin
Function	Essential for epithelial morphogenesis. May mediate Ca(2+)-regulation of exocytosis acrosomal reaction in sperm.

> Gene Ontology [ TOP ]
Biological Process	GO:0001505 regulation of neurotransmitter levels GO:0006836 neurotransmitter transport GO:0006887 exocytosis GO:0006906 vesicle fusion GO:0006979 response to oxidative stress GO:0007009 plasma membrane organization GO:0007269 neurotransmitter secretion GO:0007338 single fertilization GO:0007340 acrosome reaction GO:0007398 ectoderm development GO:0007596 blood coagulation GO:0007599 hemostasis GO:0009566 fertilization GO:0016050 vesicle organization GO:0016079 synaptic vesicle exocytosis GO:0017156 calcium ion regulated exocytosis GO:0022406 membrane docking GO:0023061 signal release GO:0030193 regulation of blood coagulation GO:0031629 synaptic vesicle fusion to presynaptic active zone membrane GO:0033194 response to hydroperoxide GO:0044091 membrane biogenesis GO:0044801 single-organism membrane fusion GO:0045026 plasma membrane fusion GO:0045055 regulated exocytosis GO:0048278 vesicle docking GO:0048284 organelle fusion GO:0048489 synaptic vesicle transport GO:0050817 coagulation GO:0050818 regulation of coagulation GO:0050878 regulation of body fluid levels GO:0051259 protein oligomerization GO:0051640 organelle localization GO:0051648 vesicle localization GO:0051650 establishment of vesicle localization GO:0051656 establishment of organelle localization GO:0061025 membrane fusion GO:0061041 regulation of wound healing GO:0071709 membrane assembly GO:0090174 organelle membrane fusion GO:0097479 synaptic vesicle localization GO:0097480 establishment of synaptic vesicle localization GO:0099003 vesicle-mediated transport in synapse GO:0099500 vesicle fusion to plasma membrane GO:0099504 synaptic vesicle cycle GO:0099531 presynaptic process involved in chemical synaptic transmission GO:0099643 signal release from synapse GO:1900046 regulation of hemostasis GO:1903034 regulation of response to wounding GO:1903575 cornified envelope assembly
Molecular Function	GO:0000149 SNARE binding GO:0005484 SNAP receptor activity GO:0048306 calcium-dependent protein binding
Cellular Component	GO:0008021 synaptic vesicle GO:0016323 basolateral plasma membrane GO:0030027 lamellipodium GO:0030133 transport vesicle GO:0031201 SNARE complex GO:0031252 cell leading edge GO:0070382 exocytic vesicle GO:0098793 presynapse GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04130 SNARE interactions in vesicular transport hsa04721 Synaptic vesicle cycle
Reactome	-

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STX2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STX2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.696	0.0142
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.587	0.687
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.771	0.441
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.023	0.953
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.164	0.91
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.157	0.933
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.166	0.657
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.334	0.82
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.086	0.955
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.171	0.869
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.88	0.541
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.102	0.495

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STX2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STX2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STX2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STX2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STX2
Name	syntaxin 2
Aliases	EPM; STX2B; STX2C; STX2A; EPIM; epimorphin; EPMA; Syntaxin-2
Chromosomal Location	12q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STX2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse STX2